Investigation of In-vitro Anticancer Activity of Letrozole Derivatives

Abstract

The increasing prevalence of cancer has driven the demand for novel therapeutic agents. This study focuses on the synthesis, characterization, and evaluation of anticancer activity of Letrozole derivatives against HeLa cell lines and other cancer types. The compounds were evaluated through NCI's tumor cell culture screening program and MTT assays. Compounds Sch.3 (58) and Sch.4 (69) demonstrated notable inhibition on HL-60 (TB) leukemia and HeLa cell lines, respectively, with Sch.4 (69) exhibiting up to 68.4% growth inhibition. This study highlights the potential of Letrozole derivatives as anticancer agents with promising efficacy across various concentrations.